Risk of gastrointestinal and hepatic toxicities in patients with cancer treated with regorafenib: A systematic review and meta- analysis of randomized controlled trials.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e22118
Abstract: e22118Background: Regorafenib is an oral small molecule inhibitor of multiple tyrosine kinases, including VEGFR, KIT, RET, RAF1, BRAF as well as PDGFR and FGFR, and is proven to be beneficial in di... read more here.
Keywords: toxicities patients; patients cancer; gastrointestinal hepatic; hepatic toxicities ... See more keywords